Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
Completed
Conditions studied: Obesity, Breast Cancer Risk
In brief
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
Key facts
- Study ID
- NCT06485089
- Run by
- University of Kansas Medical Center
- People needed
- 25
- Starts
- 2024-09-14
- Expected to finish
- 2026-03-25
- Last updated by the study team
- 2026-05-28
Who can join
Age: 40 and older, up to 64. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- • BMI 30-45 kg/m2
- Female
- Insurance approved or likely approved for tirzepatide clinical use *
- Additional risk factors for breast cancer other than obesity (any one or more) First or second degree with breast cancer Known high density on mammogram (heterogenous or extremely dense) Prior biopsy showing atypical hyperplasia or LCIS Prior treated DCIS Known carrier breast cancer predisposition gene mutation or known mutation in family member .
- 2- fold or higher estimated 10 year or lifetime risk compared to population by standard risk model (BCRAT, BCSC, IBIS
You may not qualify if…
- • Subglandular breast implants (women with subpectoral implants are eligible if C cup or greater; breast can easily be pulled off the chest wall; and with approval of PI)
- Clinical contra-indication to incretin mimetics
- Insurance/third party has denied coverage and participant does not wish to do self-pay.
- Child-bearing potential and not on contraceptives
- Prior invasive breast cancer
- Currently taking any of the following medications: insulin, tamoxifen, raloxifene, letrozole, arimidex, exemestane, incretin mimetics.
Where it is running
- University of Kansas Medical Center — Kansas City, Kansas, United States
- University of Kansas Medical Center Breast Cancer Prevention Center — Westwood, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.